Author Correction: Patient-derived induced pluripotent stem cells in cancer research and precision oncology.
In the version of this article initially published, Table 1 had several errors. In the 'Immortalized cell lines column, the 'Expansion/Scalability' was listed as 'very high' and should have been 'unlimited'. In the 'Conditional reprogramming' column 'derivation time' was listed as '2-6 months' and should have been 'a few weeks', Expansion/Scalabilty was listed as 'Unknown' and should have been 'high', 'Amenability to high throughput' was listed as 'Unknown' and should have been 'moderate', 'Modeling early stage cancer and premalignancy' was listed as 'Unknown' and should have been 'Yes', 'Amenability to genetic manipulation' was listed as 'Unknown' and should have been 'possible', 'Autologous normal controls' was listed as 'Unknown' and should have been 'yes'. In the 'Tumor-derived iPSCs' column, Expansion/Scalability was listed as 'very high' and should have been 'Unlimited'.